BDX icon

Becton Dickinson

206.44 USD
+1.81
0.88%
At close Apr 29, 4:00 PM EDT
After hours
206.44
+0.00
0.00%
1 day
0.88%
5 days
1.91%
1 month
-9.88%
3 months
-16.39%
6 months
-13.08%
Year to date
-8.85%
1 year
-11.57%
5 years
-19.94%
10 years
45.20%
 

About: Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

Employees: 74,000

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

82% more funds holding in top 10

Funds holding in top 10: 11 [Q3] → 20 (+9) [Q4]

52% more first-time investments, than exits

New positions opened: 196 | Existing positions closed: 129

16% more call options, than puts

Call options by funds: $320M | Put options by funds: $276M

3% more funds holding

Funds holding: 1,551 [Q3] → 1,591 (+40) [Q4]

2.31% more ownership

Funds ownership: 87.75% [Q3] → 90.06% (+2.31%) [Q4]

1% less capital invested

Capital invested by funds: $61.1B [Q3] → $60.4B (-$642M) [Q4]

15% less repeat investments, than reductions

Existing positions increased: 537 | Existing positions reduced: 631

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$260
26%
upside
Avg. target
$261
26%
upside
High target
$261
26%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Jason Bednar
27% 1-year accuracy
10 / 37 met price target
26%upside
$260
Overweight
Maintained
23 Apr 2025
Barclays
Travis Steed
29% 1-year accuracy
2 / 7 met price target
26%upside
$261
Overweight
Maintained
7 Apr 2025

Financial journalist opinion

Based on 15 articles about BDX published over the past 30 days

Positive
Seeking Alpha
7 hours ago
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Edison (+25.65%), Cardinal Health (+17.82%), and Coca-Cola (+16.18%). 33 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.33%.
Best Dividend Aristocrats For May 2025
Neutral
PRNewsWire
10 hours ago
BD Board Declares Dividend
FRANKLIN LAKES, N.J. , April 29, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025.
BD Board Declares Dividend
Positive
Zacks Investment Research
1 day ago
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
Positive
Zacks Investment Research
1 day ago
Gear Up for Becton Dickinson (BDX) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Gear Up for Becton Dickinson (BDX) Q2 Earnings: Wall Street Estimates for Key Metrics
Neutral
Seeking Alpha
3 days ago
Becton, Dickinson and Company: It's Wait And See For Me
Becton, Dickinson and Company is a leading medical device firm specializing in medical supplies, devices, laboratory equipment, and diagnostic products. BDX operates in three segments: BD Medical, BD Life Sciences, and BD Interventional, with plans to spin off its Biosciences and Diagnostic Solutions business in 2026. BDX has struggled over the past decade, with a 10-year CAGR of only 5.1%.
Becton, Dickinson and Company: It's Wait And See For Me
Positive
Seeking Alpha
6 days ago
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY.
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
Neutral
PRNewsWire
6 days ago
BD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair
Phasix™ ST Umbilical Hernia Patch Leverages Same Surgical Technique as Permanent Mesh Procedures  FRANKLIN LAKES, N.J. , April 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the commercial launch of Phasix™ ST Umbilical Hernia Patch, the first and only fully absorbable hernia patch on the market designed specifically for umbilical hernias.
BD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair
Negative
Zacks Investment Research
1 week ago
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
Neutral
PRNewsWire
1 week ago
BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support
HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations FRANKLIN LAKES, N.J. , April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.
BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support
Neutral
Seeking Alpha
1 week ago
DGI For The DIY: 2024 Dividend Portfolio Review
This portfolio focuses on generating a growing stream of dividend income by investing in companies that consistently increase dividends. I reinvest dividends into more shares of the companies I already own to compound growth. The investment strategy is guided by specific principles to ensure consistent and disciplined investing.
DGI For The DIY: 2024 Dividend Portfolio Review
Charts implemented using Lightweight Charts™